Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06945458 · ClinicalTrials.gov registry record · Phase 1
Safety, PK, PD, and Clinical Activity of Orally Administered KT-621 in Adult Patients With Atopic Dermatitis (AD)
A Phase 1 study of Atopic Dermatitis, sponsored by Kymera Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 22
- Enrollment target
- 12
- Study locations
NCT06945458: Completed Phase 1 study of Atopic Dermatitis, sponsored by Kymera Therapeutics.
NCT06945458 is a Phase 1 study of Atopic Dermatitis that has completed, run by Kymera Therapeutics. The registered enrollment target is 22 participants, below the 609-participant average among 150 other Atopic Dermatitis trials with a reported enrollment target (96% lower). The trial reports 12 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06945458, a Phase 1 study of Atopic Dermatitis, has completed, sponsored by Kymera Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 22 participants
- Enrollment target
- 12
- Study locations
Study Summary
This is a study to evaluate safety, tolerability, pharmacokinetics, pharmacodynamics, and clinical activity of orally administered KT-621 in adult male and female patients with moderate to severe atopic dermatitis (AD).
Conditions Studied
Interventions
- DRUG KT-621
Study Locations (12)
Florida
- Kymera Investigative Site - Boynton Beach
- Kymera Investigative Site - Hollywood
- Kymera Investigative Site - Tampa
California
- Kymera Investigative Site - Fountain Valley
- Kymera Investigative Site - Santa Monica
Ohio
- Kymera Investigative Site - Dublin
- Kymera Investigative Site - Springfield
Alabama
- Kymera Investigative Site - Birmingham
North Dakota
- Kymera Investigative Site - Fargo
Oklahoma
- Kymera Investigative Site - Tulsa
South Carolina
- Kymera Investigative Site - Charleston
Texas
- Kymera Investigative Site - San Antonio
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2025-04-17 |
| Est. Completion | 2025-11-10 |
| Phase | Phase 1 |
What the finished NCT06945458 record still lists
NCT06945458 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 22 participants, a relatively small participant target, below the 609-participant average among 150 other Atopic Dermatitis trials with a reported enrollment target (96% lower).
The record links to 1 condition, with Atopic Dermatitis appearing as the primary indexed condition, and to 1 intervention - of which KT-621 is the first listed.
NCT06945458 lists 12 locations in 8 states (Florida, California, Ohio).
Frequently Asked Questions
What is clinical trial NCT06945458 about?
NCT06945458 is a clinical study titled "Safety, PK, PD, and Clinical Activity of Orally Administered KT-621 in Adult Patients With Atopic Dermatitis (AD)". This is a study to evaluate safety, tolerability, pharmacokinetics, pharmacodynamics, and clinical activity of orally administered KT-621 in adult male and female patients with moderate to severe atopic dermatitis (AD).
What is the current status of trial NCT06945458?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 22 participants. The study started on 2025-04-17. Estimated completion is 2025-11-10.
What conditions does trial NCT06945458 study?
This clinical trial studies the following conditions: Atopic Dermatitis.
What interventions are being tested in trial NCT06945458?
The interventions under investigation include: KT-621 (DRUG).
Who is sponsoring clinical trial NCT06945458?
This trial is sponsored by Kymera Therapeutics, which has 10 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06945458 being conducted?
This trial has 12 study locations across Alabama, California, Florida, North Dakota, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Atopic Dermatitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06945458's enrollment target sits among peer trials
22 132nd of 150 higher than 18 of 150 other Atopic Dermatitis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Atopic Dermatitis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Evaluating the Safety and Tolerability of Baricitinib in Patients With Job Syndrome With Lupus-Like Disease and/or Atopic Dermatitis
RECRUITING · Phase 1
-
Targeted Investigation of Microbiome 2 Treat Atopic Dermatitis (TIME-2)
RECRUITING · Phase 1
-
FIH Study to Evaluate the Tolerability of PF-07832837 in Healthy Adults and Patients
RECRUITING · Phase 1
-
A Study to Investigate the Safety, Tolerability, and Efficacy of BxC-I17e Single and Multiple Dose SC Injection in Patients With Moderate to Severe Atopic Dermatitis
RECRUITING · Phase 1
-
A Study of BBT001 in Healthy Volunteers (HVs) and in Adult Patients With Atopic Dermatitis (AD)
RECRUITING · Phase 1
-
A Study to Learn If the Study Medicine Called PF-08049820 Changes How the Body Processes the Other Study Medicines Called Oral Contraceptives, Midazolam, and Dabigatran in Healthy Adult Female Participants
ACTIVE NOT RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02508038 · 22 participants · Phase 1
Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors
- NCT03099356 · 22 participants · Phase 2
Cyclophosphamide and Sirolimus for the Treatment of Metastatic, RAI-refractory, Differentiated Thyroid Cancer
- NCT03676647 · 22 participants
Diagnostic DNA Methylation Signature in Diagnosing Thyroid Cancer After Fine-Needle Aspiration in Patients With Thyroid Nodules
- NCT04569591 · 22 participants · NA
DDAVP for Pituitary Adenoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI